Navigation Links
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
Date:6/9/2008

SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA). The data were presented during the Federation of Clinical Immunology Societies (FOCIS) meeting being held this week in Boston, MA.

Researchers examined the impact of treatment with PCI-32765 on mouse models of rheumatoid arthritis at disease onset, and with established active disease. Treatment prevented further joint swelling when animals were dosed at early stages of disease. In animals with advanced disease, treatment with PCI-32765 reduced inflammation and induced regression of disease with approximately 50% reduction in histopathologic score after only five days of dosing. Treatment with PCI-32765 was found to inhibit mast cell function and to prevent allergic reaction, with passive cutaneous analphylaxis inhibited by more than 95%. In other studies, human B-cell activation was shown to be selectively inhibited by drug treatment in vitro. PCI-32765 also inhibited the proliferation of, and induced apoptosis in, multiple B-cell lymphoma cell lines in vitro, suggesting that Btk inhibition could be a novel drug target in lymphoma.

"This study suggests that treatment with PCI-32765 causes a potent combined blockade of both B-cell and mast cell activation," said Joseph J. Buggy, Ph.D., vice president of research for Pharmacyclics. "This dual blockade may account for the preclinical efficacy seen in established arthritis models and holds promise for potential use in humans with advanced RA and other immune
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
2. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
3. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
6. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
9. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
10. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
11. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... DUBLIN , June 29, 2015 ... the addition of the "Pharmaceutical Packaging Market in ... The pharmaceutical packaging market in North ... 5.31% over the period 2014-2019. International ... bodies on drug manufacturers, which in turn fuels adoption ...
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... ATLANTA , July 6, 2015 Celtaxsys, ... anti-inflammatory therapeutics, including those with rare and orphan inflammatory ... from the U.S. Food and Drug Administration (FDA) to ... drug candidate, acebilustat (CTX-4430), in adult CF patients in ... in Europe will be filed ...
Breaking Medicine Technology:North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
(Date:7/6/2015)... ... ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led a ... available tests that better incorporate personalized medicine into diagnosing the condition. , Their ... published in the July issue of the scientific journal Thyroid . The ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... Virginia (PRWEB) , ... July 06, 2015 , ... ... choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ... For a particular demographic, however, fat reduction has become more than a way ...
(Date:7/6/2015)... OH (PRWEB) , ... July 06, 2015 , ... ... the proper reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, ... their coding expertise with their Top 10 Tips for ICD-10. The ten tips ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... SALT LAKE CITY, Dec. 15 The new compact LifeSpan TR200 ... ), was highly praised by treadmill review groups in recent ... treadmill received awards for Best New Treadmill, Recommended Unique Design, and ... is designed for light use walking indoors in small workout spaces. ...
... study links chronic obstructive pulmonary disease, or COPD, with ... activate the body,s immune system. The University ... awareness of the immune system,s role in COPD, a ... million Americans with wheezing, shortness of breath, chest tightening ...
... increases risk in teens, study suggests , TUESDAY, Dec. ... obese increases the risk of obstructive sleep apnea, but ... younger children, Australian researchers have found. , In sleep ... 18, who were referred for evaluation of snoring and ...
... potential for injury when doctors decide benefits of imaging ... -- MRI scans can pose a serious risk to ... and Drug Administration researchers exposed pacemakers to a simulated ... produced at the tip of the pacemaker lead, where ...
... , ... Reportlinker.com announces that a new market research ... In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. ... , http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html , The newly published ...
... , , NEW YORK, ... new market research report is available in ... Cardiovascular Diseases Therapeutics - Market Forecasts to ... Analysis , http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , ...
Cached Medicine News:Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: